09823283

FILE 'HOME' ENTERED AT 10:50:21 ON 29 APR 2002

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:50:32 ON 29 APR 2002

STRUCTURE FILE UPDATES: 28 APR 2002 HIGHEST RN 408492-65-9
DICTIONARY FILE UPDATES: 28 APR 2002 HIGHEST RN 408492-65-9

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

*** YOU HAVE NEW MAIL ***

=>
Uploading 09823283.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 10:50:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 999 TO ITERATE

100.0% PROCESSED 999 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L2 9 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL

```
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                140.28     140.49

FILE 'CAPLUS' ENTERED AT 10:51:09 ON 29 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Apr 2002  VOL 136 ISS 18
FILE LAST UPDATED: 28 Apr 2002  (20020428/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

*** YOU HAVE NEW MAIL ***

=> s l1
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




SAMPLE SEARCH INITIATED 10:51:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     43 TO ITERATE

100.0% PROCESSED      43 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          467 TO     1253
PROJECTED ANSWERS:               1 TO       80

L3             1 SEA SSS SAM L1



L4             1 L3

=> s l2
L5             7 L2

=> d l7 bib abs hitstr 1-7
L7 NOT FOUND
The L-number entered has not been defined in this session, or it
```

has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l5 bib abs hitstr 1-7

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2002:107826 CAPLUS
DN 136:172758
TI Terminally-branched polymeric linkers containing extension moieties for prodrug conjugates
IN Greenwald, Richard B.; Choe, Yun H.
PA USA
SO U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002015691	A1	20020207	US 2001-823296	20010329
PRAI US 2000-193931P	P	20000331		

AB The present invention relates to polymer-based (e.g., PEG) conjugates having increased therapeutic payloads. In particular, the invention relates to the use of extension moieties which increase the efficiency of the loading of drugs onto the polymeric carriers. A variety of prodrugs were prepd. from ara-C and PEG derivs. by using spacer groups. The prodrug demonstrated better antitumor activity than ara-C alone. The prodrug produced complete tumor regression.

IT **396134-08-0P 396134-17-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terminally-branched polymeric linkers contg. extension moieties for prodrug conjugates)

RN 396134-08-0 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[18-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4,4-bis[14-[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-3,14-dioxo-7,10-dioxa-4,13-diazatetradec-1-yl]-2,7,18-trioxo-11,14-dioxa-3,8,17-triazaoctadec-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)



PAGE 1-B



PAGE 1-C



PAGE 2-B



PAGE 3-B



RN 396134-17-1 CAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-methyl-.omega.-hydroxy-, 1-ether with N-(hydroxyacetyl)-L-aspartoylbis[N1,N4-bis[2-[2-[2-[[[(1-.beta.-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)amino]carbonyl]amino]ethoxy]ethoxy]ethyl]-L-aspartamide] (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 4-B



L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 2001:75282 CAPLUS
DN 134:136702
TI Enhanced circulation effector composition and method
IN Zalipsky, Samuel; Woodle, Martin C.; Martin, Francis J.; Barenholz, Yechezkel
PA Sequus Pharmaceuticals, Inc., USA
SO U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 316,436, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 6180134 B1 20010130 US 1995-480332 19950607
US 6326353 B1 20011204 US 1993-35443 19930323
US 2001043929 A1 20011122 US 2001-877978 20010608
PRAI US 1993-35443 A2 19930323
US 1994-316436 B2 19940929
US 1995-480332 A1 19950607

AB A liposome compn. comprising small, surface-bound effector mols. is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector mols. are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock. Liposomes with covalently bound .beta.- galactosidase were prepd. from a maleimide deriv. of distearyl phosphatidyl ethanolamine carbamide of PEG bis(amine), .alpha.-tocopherol, cholesterol, partially hydrogenated egg phosphatidylcholine, egg phosphatidyl glycerol, and .beta.-galactosidase.

IT **159125-99-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of polyethylene glycol derivs. for liposomes contg. polypeptides or polysaccharide effector mols. covalently attached therewith)

RN 159125-99-2 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[(2Z)-3-carboxy-1-oxo-2-propenyl]amino]ethyl]-.omega.-[[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **159158-15-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyethylene glycol derivs. for liposomes contg. polypeptides or polysaccharide effector mols. covalently attached therewith)

RN 159158-15-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

— $(CH_2)_{16}$ — Me

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 1999:78360 CAPLUS
DN 130:175340
TI Thermal printing material containing phenolic compound as color developer
IN Shimada, Masaru; Matsui, Hiroaki; Torii, Masaaki
PA Ricoh Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11028868	A2	19990202	JP 1997-197918	19970708

OS MARPAT 130:175340
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title material comprises a support coated with a heat-sensitive layer contg. a leuco dye and, as a color developer, a phenolic compd. selected from I-VI (X = hydrocarbon, alkoxy, halo, H; n = 1-3; m = 0-2; p = 0-2 in I and II, p = 1-10 in III-VI; q1, q2, q3 = 1-10; q4 = 0-21). The material provides high d. and low fog images with good plasticizer resistance and water resistance.
IT **220427-37-2 220427-38-3 220427-40-7**

220427-42-9
RL: TEM (Technical or engineered material use); USES (Uses)
(thermal printing material contg. phenolic compd. as color developer)

RN 220427-37-2 CAPLUS
CN 5,8-Dioxa-2,11-diazatridecanamide, 13-(4-hydroxyphenyl)-N-octadecyl-12-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 220427-38-3 CAPLUS
CN 5,8-Dioxa-2,11-diazatetradecanamide, 14-(4-hydroxyphenyl)-N-octadecyl-12-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 220427-40-7 CAPLUS
CN 5,8-Dioxa-2,11-diazatridecanamide, 13-[(4-hydroxyphenyl)amino]-N-octadecyl-12-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 220427-42-9 CAPLUS
CN 5,8-Dioxa-2,11-diazatetradec-13-enamide, 14-(4-hydroxyphenyl)-N-octadecyl-12-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 1997:308339 CAPLUS
DN 126:334416
TI Liposomes for treatment of B-cell and T-cell disorders
IN Allen, Theresa M.; Martin, Francis J.
PA Sequus Pharmaceuticals, Inc., USA
SO U.S., 31 pp. Cont.-in-part of U.S. 5,527,528.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5620689	A	19970415	US 1995-475050	19950607
	US 5013556	A	19910507	US 1989-425224	19891020
	AU 9066374	A1	19910516	AU 1990-66374	19901019
	AU 642679	B2	19931028		
	EP 496813	A1	19920805	EP 1990-916409	19901019
	EP 496813	B1	19941214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05505173	T2	19930805	JP 1990-515238	19901019
	JP 2001181214	A2	20010703	JP 2001-4291	19901019
	US 5213804	A	19930525	US 1991-642321	19910115
	NO 9201213	A	19920604	NO 1992-1213	19920327
	FI 9201763	A	19920421	FI 1992-1763	19920421
	US 5527528	A	19960618	US 1993-40544	19930331
	JP 10001431	A2	19980106	JP 1997-63661	19970317
	JP 2889549	B2	19990510		
PRAI	US 1989-425224	A2	19891010		
	US 1991-642321	A2	19910115		
	US 1993-40544	A2	19930331		
	JP 1990-515238	A3	19901019		

JP 1991-501034 A3 19901019
WO 1990-US6034 A 19901019

AB A method of treating a subject having a disorder characterized by a neoplasm of B-lymphocyte or T-lymphocyte lineage cells is described. The method includes administering a suspension of liposomes having a surface coating of polyethylene glycol chains. Attached to the distal ends of the chains are antibodies or antibody fragments effective to bind to an antigen specific to the affected cells. In one embodiment, anti-CD19 antibodies are attached to the liposome-bound chains, for treatment of multiple myeloma. An example PEG compd., distearoylphosphatidylethanolamine PEG hydrazide deriv. was prepd.

IT **159158-15-3DP**, reaction products with antibodies
159158-15-3P 179267-38-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(liposomes for treatment of B-cell and T-cell disorders)

RN 159158-15-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 159158-15-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 179267-38-0 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[(3-carboxy-1-oxo-2-propenyl)amino]ethyl]-.omega.-[[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS

AN 1996:449885 CAPLUS
DN 125:105097
TI Solid tumor treatment method using antitumor agent-containing liposomes with PEG coating and surface-attached antibody
IN Allen, Theresa M.; Martin, Francis J.
PA Sequus Pharmaceuticals, Inc., USA
SO U.S., 17 pp. Cont.-in-part of U.S. 5,213,804.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5527528	A	19960618	US 1993-40544	19930331
	US 5013556	A	19910507	US 1989-425224	19891020
	AU 9066374	A1	19910516	AU 1990-66374	19901019
	AU 642679	B2	19931028		
	EP 496813	A1	19920805	EP 1990-916409	19901019
	EP 496813	B1	19941214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05505173	T2	19930805	JP 1990-515238	19901019
	JP 2001181214	A2	20010703	JP 2001-4291	19901019
	US 5213804	A	19930525	US 1991-642321	19910115
	NO 9201213	A	19920604	NO 1992-1213	19920327
	FI 9201763	A	19920421	FI 1992-1763	19920421
	WO 9422429	A1	19941013	WO 1994-US3457	19940330
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9465272	A1	19941024	AU 1994-65272	19940330
	US 5620689	A	19970415	US 1995-475050	19950607
	JP 10001431	A2	19980106	JP 1997-63661	19970317
	JP 2889549	B2	19990510		
PRAI	US 1989-425224	A2	19891020		
	US 1991-642321	A2	19910115		
	JP 1990-515238	A3	19901019		
	JP 1991-501034	A3	19901019		
	WO 1990-US6034	A	19901019		
	US 1993-40544	A2	19930331		
	WO 1994-US3457	W	19940330		

AB A method of administering an antitumor compd. to a subject is disclosed. The method includes administering liposomes having sizes predominantly in the range 0.05 to 0.12 .mu., and contg. an antitumor compd. in liposome-entrapped form, a surface coating of polyethylene glycol chains, at a surface concn. thereof sufficient to extend the blood circulation time of the liposomes severalfold over that of liposomes in the absence of such coating, and surface-attached antibody mols. effective to bind specifically to tumor-assocd. antigens present at the tumor site. One liposome compn. includes doxorubicin in entrapped form, and, on the liposome surface, a monoclonal antibody against highly proliferating cells in a lung squamous cell carcinoma.

IT **179267-38-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction; antitumor agent-contg. liposome prepn. with PEG coating and surface-attached antibody for solid tumor treatment)
RN 179267-38-0 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[(3-carboxy-1-oxo-2-propenyl)amino]ethyl]-.omega.-[[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)





L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 1995:196581 CAPLUS
DN 122:38832
TI Pharmaceutical liposomes comprising PEG for administration of polypeptides
IN Zalipsky, Samuel; Martin, Francis
PA Liposome Technology, Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9421281	A1	19940929	WO 1994-US3102	19940322
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9463683	A1	19941011	AU 1994-63683	19940322
PRAI	US 1993-35640		19930323		
	WO 1994-US3102		19940322		

AB Pharmaceutical liposomes comprising PEG are prepd. for administration of polypeptides. Liposomes contg. biotin-PEG were incubated in the presence of avidin. Avidin-coated liposomes were incubated with biotinylated IgG to obtain liposome-bound antibody.

IT **159125-99-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(pharmaceutical liposomes comprising PEG for administration of polypeptides)

RN 159125-99-2 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[(2Z)-3-carboxy-1-oxo-2-propenyl]amino]ethyl]-.omega.-[[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS
AN 1994:686620 CAPLUS
DN 121:286620
TI Pharmaceutical liposomes comprising hydrophilic polymer conjugates with polypeptides or polysaccharides
IN Zalipsky, Samuel; Woodle, Martin C.; Martin, Francis J.; Barenholz, Yechezkel
PA Liposome Technology, Inc., USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9421235	A1	19940929	WO 1994-US3103	19940322
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6326353	B1	20011204	US 1993-35443	19930323
	CA 2157410	AA	19940929	CA 1994-2157410	19940322
	AU 9463684	A1	19941011	AU 1994-63684	19940322
	EP 689428	A1	19960103	EP 1994-910988	19940322
	EP 689428	B1	19990120		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, LU, NL, SE				
	JP 08508256	T2	19960903	JP 1994-521332	19940322
	AT 175868	E	19990215	AT 1994-910988	19940322
	ES 2131190	T3	19990716	ES 1994-910988	19940322
PRAI	US 1993-35443	A	19930323		
	WO 1994-US3103	W	19940322		

AB A liposome compn. comprising small, surface-bound effector mols., such as .beta.-galactosidase (I), is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, such as PEG, for enhanced circulation time in the bloodstream. The effector mols. are attached to the distal ends of the polymer chains. Maleic acid deriv. of distearoylphosphatidylcholine (DSPE) carbamide of PEG bis(amine) was heated with acetic anhydride satd. with anhyd. NaCH3COO for 2 h at 50.degree. to obtain maleimide of DSPE carbamide of PEG bis(amine) (II) which was purified to a pale yellow, viscous oil. I liposomes with covalently-bound II was prepd.

IT **159125-99-2P 159158-15-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(pharmaceutical liposomes comprising hydrophilic polymer conjugates with polypeptides or polysaccharides)

RN 159125-99-2 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[(2Z)-3-carboxy-1-oxo-2-propenyl]amino]ethyl]-.omega.-[[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 159158-15-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[9-hydroxy-9-oxido-4,15-dioxo-12-[(1-oxooctadecyl)oxy]-8,10,14-trioxa-3,5-diaza-9-phosphadotriacont-1-yl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



— $(CH_2)_{16}$ — Me

=>